PeptideSchool Research
Research guides built to keep claims, evidence, math, and uncertainty connected.
Browse educational profiles, research methods, comparisons, unit explainers, and evidence terms. Every page identifies its sources and the boundary between a useful research observation and a personal medical decision.
Published by PeptideSchool Editorial Desk · Educational content only. Not medical advice.
Research operations
Discover, verify, and follow the public research system.
These public tools connect the guide collection to its discovery paths, source records, reproducibility assets, and dated updates.
Find relevant research profiles
Choose broad research interests and discover matching library profiles without receiving a treatment recommendation.
Open the research finderAudit the public source inventory
Review the article families, dates, institutional bylines, source publishers, and related-reading coverage behind the public guide collection.
Inspect the source inventoryVerify calculator test data
Use versioned synthetic test vectors, schemas, and checksums to inspect the calculator's unit-conversion and rejection logic.
Review the test vectorsFollow research and regulatory changes
Move between the dated change timeline and source-led News reports while keeping evidence boundaries visible.
Read the Research RadarInspect the search intent landscape
Review the aggregate methodology and nine privacy-preserving clusters derived from 7,974 US Keyword Planner suggestions.
Explore the search landscape15 guides
Research profiles
retatrutide research
Retatrutide: triple-agonist design, phase 2 evidence, and open questions
Retatrutide is an investigational single molecule designed to activate GIP, GLP-1, and glucagon receptors. Its phase 2 results generated substantial interest, but confirmation, long-term outcomes, and indication-specific regulatory review depend on later-stage evidence.
Read guidetirzepatide research
Tirzepatide: dual-agonist biology, trial evidence, and interpretation
Tirzepatide is a GIP and GLP-1 receptor agonist studied across type 2 diabetes and chronic weight-management programs. Strong human evidence exists, but conclusions remain tied to the studied population, labeled indication, duration, and comparator.
Read guidesemaglutide research
Semaglutide: GLP-1 receptor biology, STEP evidence, and limits
Semaglutide is a GLP-1 receptor agonist with extensive human evidence across defined indications. The STEP 1 trial is a key weight-management study, but responsible interpretation keeps formulation, population, comparator, duration, and safety attached to the result.
Read guidemazdutide research
Mazdutide: GLP-1/glucagon dual agonism and the clinical evidence
Mazdutide, also known as IBI362, is a dual GLP-1 and glucagon receptor agonist developed through a clinical program in China. Early and mid-stage randomized evidence is informative, while comparisons with other incretin programs remain indirect unless tested head to head.
Read guideMOTS-c research
MOTS-c: mitochondrial encoding, metabolic research, and evidence limits
MOTS-c is a short peptide encoded within mitochondrial DNA and studied as a signal linking mitochondrial state with cellular metabolism and stress responses. Foundational evidence is scientifically important but predominantly preclinical, leaving human effects and safety unresolved.
Read guideSS-31 research
SS-31 (elamipretide): mitochondrial targeting, trials, and narrow regulatory context
SS-31 is a synthetic mitochondria-targeted tetrapeptide developed as elamipretide. Its evidence spans mechanism studies and indication-specific human trials, including a randomized Barth syndrome program whose primary period and later extension require separate interpretation.
Read guideGHK-Cu research
GHK-Cu: copper-binding biology, experimental evidence, and claim limits
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. Its broad experimental literature is frequently overextended into product and whole-body promises, making molecular identity and evidence level especially important.
Read guideBPC-157 research
BPC-157: what preclinical research suggests and human evidence cannot yet show
BPC-157 is a synthetic 15-amino-acid research peptide discussed for tissue and gastrointestinal models. The evidence base is dominated by animal and laboratory studies, so strong human recovery or healing claims exceed what the literature can establish.
Read guideendogenous GLP-1 biology
Endogenous GLP-1 Is a Processed Product of Proglucagon
Endogenous glucagon-like peptide-1 is best understood through its precursor context, mature forms, receptor signaling, measurement methods, and evidence boundaries.
Read guideendogenous GIP biology
Endogenous GIP as a Nutrient-Responsive Peptide Hormone
Glucose-dependent insulinotropic polypeptide has a defined gene, mature chain, secretion pattern, metabolism, and receptor system. Assay limits determine how confidently each layer can be measured.
Read guideglucagon biology explained
Glucagon Is One Product of a Multi-Peptide Precursor
Endogenous glucagon connects precursor biology, a defined mature peptide, receptor action, and experimental readouts. Each layer answers a different question.
Read guideinsulin biosynthesis and signaling
From Preproinsulin to Two-Chain Insulin
Endogenous insulin is produced through precursor processing, forms a disulfide-linked mature structure, and acts through regulated secretion and receptor signaling.
Read guideC-peptide biology and measurement
C-Peptide Connects the Insulin Chains Before Processing
Connecting peptide has a defined role in insulin biosynthesis and a separate use as a circulating measurement. Proposed functions beyond those roles remain an active evidence question.
Read guidesomatostatin biology explained
Somatostatin-14 and Somatostatin-28 Share a Precursor
Endogenous somatostatin is produced in more than one mature form and signals through a diverse receptor family. Precursor processing, local action, and measurement limits shape how the evidence should be read.
Read guideghrelin biology explained
Ghrelin Requires a Specific Acyl Modification for Canonical GHSR Signaling
Endogenous ghrelin depends on sequence processing and octanoylation, while receptor pharmacology and assay specificity provide separate evidence layers.
Read guide18 guides
Science topics
incretin agonists
Incretin agonists: a map of GLP-1, GIP, and glucagon research
Incretin-related medicines and investigational molecules are often grouped together even when they engage different receptors. This overview maps single-, dual-, and triple-agonist research and explains why cross-trial rankings require caution.
Read guidemitochondrial-derived peptides
Mitochondrial-derived peptides and mitochondria-targeted peptide research
MOTS-c and SS-31 often appear in the same mitochondrial research conversation, but they belong to different biological categories. MOTS-c is an endogenous mitochondrial-derived signaling peptide, while SS-31 is a synthetic mitochondria-targeted compound.
Read guidegrowth hormone secretagogues
Growth hormone secretagogues: classes, signals, and evidence limits
Growth hormone secretagogue is an umbrella term, not the name of a single molecule. The category includes GHRH-pathway analogs and ghrelin-receptor agonists, and a measured hormone change is not the same as a proven health outcome.
Read guidecopper-binding peptides
Copper-binding peptides: GHK-Cu, AHK-Cu, and the evidence map
Copper-binding peptides are defined by coordination chemistry as well as amino-acid sequence. GHK-Cu and AHK-Cu have distinct identities, and their experimental records do not support universal cosmetic or medical promises.
Read guidepeptide hormones explained
How Peptide Hormones Are Made, Released, and Detected
Peptide hormones begin as gene-encoded precursors, undergo proteolytic processing, and act through regulated secretion and receptor-mediated signaling. Understanding the system requires following each of those steps.
Read guideneuropeptides explained
Neuropeptides as Slow, Context-Dependent Neural Signals
Neuropeptides complement classical neurotransmitters through distinct patterns of processing, release, diffusion, and receptor signaling.
Read guideantimicrobial peptides explained
Antimicrobial Peptides Are More Than Membrane-Disrupting Molecules
Host-defense and microbial peptides span diverse sequences and experimental mechanisms. Their scientific promise must be read alongside resistance, selectivity, stability, and other limits on translation.
Read guidecyclic peptides explained
How Cyclization Changes Peptide Structure and Function
Cyclic peptides differ in ring topology, conformational constraint, biosynthesis, and synthetic design. Those structural features shape their behavior but do not establish biological or clinical value on their own.
Read guidepeptide therapeutics development
The Evidence Chain Behind Peptide Therapeutic Development
Moving from an interesting peptide sequence to a controlled therapeutic product requires evidence across identity, activity, exposure, safety, manufacturing, and regulatory review.
Read guidepeptide delivery challenges
Why Peptide Delivery Is a Multibarrier Research Problem
Activity in vitro does not guarantee controlled exposure in vivo. Biological barriers, degradation, distribution, formulation, and product quality all stand between those two observations.
Read guidepeptide half-life extension strategies
How Peptide Half-Life Extension Strategies Change a Molecule
Half-life extension can slow degradation, alter distribution, or reduce clearance. Each strategy changes more than duration and carries product-specific trade-offs.
Read guidepeptide lipidation explained
How Lipidation Changes Peptide Distribution and Persistence
In a lipidated peptide, the lipid, linker, and attachment site are part of the molecular design. Each can affect binding, distribution, stability, and exposure.
Read guidepeptide PEGylation explained
PEGylated Peptides Require More Than a Molecular-Weight Label
Conjugating polyethylene glycol changes product identity as well as size. The polymer introduces analytical, distribution, clearance, activity, and immune considerations that require direct evidence.
Read guidepeptide fusion proteins explained
How Fusion Partners Change Peptide Products
Genetically encoded peptide fusions combine a peptide with a partner through a defined linker. The partner, linker, and expression system all introduce product-quality questions.
Read guidepeptide receptor signaling
Peptide Binding Is Only the First Step in Receptor Signaling
Ligand binding, receptor activation, pathway coupling, cellular output, and organism-level response are related but distinct evidence layers.
Read guidereceptor desensitization and internalization
Why Receptor Signaling Changes During Continued Stimulation
Receptor regulation changes over time. Reduced signaling, physical internalization, trafficking fate, and broader cellular adaptation should be measured separately.
Read guidepeptide immunogenicity explained
How Peptide Immunogenicity Risk Is Assessed
Peptide immunogenicity can involve innate and adaptive immune pathways, but in silico and in vitro signals do not establish a clinical outcome.
Read guidepeptidomimetics explained
How Peptidomimetics Reproduce Selected Peptide Features
Peptidomimetics reproduce selected recognition features of a peptide without necessarily retaining a conventional peptide backbone.
Read guide7 guides
Comparisons
tirzepatide vs retatrutide vs mazdutide
Tirzepatide vs retatrutide vs mazdutide: receptors, trials, and comparison limits
Tirzepatide, retatrutide, and mazdutide occupy overlapping areas of incretin research, but they activate different receptor combinations and sit at different stages of evidence development. Those differences matter more than an unsupported cross-trial ranking.
Read guideSS-31 vs MOTS-c
SS-31 vs MOTS-c: origin, mechanism, evidence, and development status
SS-31 and MOTS-c are often paired because both appear in mitochondrial research. Their origins, structures, proposed actions, translational evidence, and regulatory histories are different, so a shared theme should not be mistaken for equivalence.
Read guidepercent solution vs ratio strength
Percent Solutions, Ratio Strength, and ppm Are Not Interchangeable
Percent solutions, ratio strength, and parts per million can look self-explanatory. Each still needs a clear numerator, denominator, and measurement basis before it can be interpreted.
Read guiderelative risk vs absolute risk vs odds ratio
Relative Risk, Absolute Risk, and Odds Ratios Are Different Measures
Relative risk, absolute risk, and odds ratios describe binary outcomes from different angles. Their denominators and null values matter, especially when a relative effect is reported without the underlying absolute risk.
Read guidepreclinical vs clinical evidence
Preclinical vs Clinical Evidence: What Each Can Support
Laboratory models, animal studies, observational research, and randomized trials answer different questions. Knowing those boundaries helps prevent an early finding from being presented as established human evidence.
Read guidemolarity vs mass concentration
Molarity vs Mass Concentration: What Each One Measures
Molarity measures amount of substance per volume; mass concentration measures mass per volume. Converting between them requires the molecule's identity and molar mass.
Read guideoxytocin vs vasopressin
Oxytocin and Vasopressin Are Related but Distinct Peptide Systems
Oxytocin and vasopressin are related neurohypophyseal nonapeptides, but their precursors, receptors, assays, and behavioral evidence must remain distinct.
Read guide38 guides
Research methods
peptide literature search
A reproducible method for searching peptide literature
A reliable peptide search starts with a focused question and leaves a clear record of what was searched, selected, and excluded. The workflow below helps readers find scientific literature without treating search results as medical guidance.
Read guidehow to check a PubMed citation
How to verify a PubMed citation before using it
A citation can be authentic and still fail to support the sentence attached to it. Learn how to verify the paper first, then test whether its evidence actually supports the claim.
Read guidehow to read ClinicalTrials.gov
How to read ClinicalTrials.gov without overclaiming
A trial registry describes a study record, not necessarily a completed study or a positive result. The fields below can answer development questions, but they cannot establish effectiveness on their own.
Read guidepeptide claim checklist
A claim-checking checklist for peptide research
Peptide claims often become broader as they move from a paper to social copy. This checklist helps readers return each statement to the evidence type, population, and outcome that actually support it.
Read guidemeasurement uncertainty significant figures
Measurement Uncertainty, Precision, and Significant Figures
Resolution, repeatability, accuracy, and uncertainty describe different parts of a measurement. Keeping them separate leads to a more honest reading of both measured and derived values.
Read guidep-values and statistical significance explained
P-Values and Statistical Significance: What They Do Not Prove
A p-value is one output from a hypothesis test, not a verdict on importance or truth. Read it alongside the study design, effect estimate, uncertainty, and number of tests performed.
Read guidehow to read a randomized controlled trial
How to Read a Randomized Controlled Trial Step by Step
Read a randomized controlled trial from its protocol question through its design, results, and applicability. The abstract conclusion is only one part of that record.
Read guidehow to read a systematic review and meta-analysis
How to Read a Systematic Review and Meta-Analysis
A pooled estimate is only as credible as the studies and analytic choices behind it. Learn what to check before treating a meta-analysis as a single definitive answer.
Read guidehow to read syringe graduations
How to Read Syringe Graduations in a Non-Clinical Research Context
Learn how to interpret, document, and check a device scale without turning that reading into injection, administration, or personal amount guidance.
Read guidehow to read scientific graphs and tables
Reading Research Tables, Error Bars, and Logarithmic Axes
Before drawing a biological or statistical conclusion, identify exactly what a table or graph reports, including its axes, scale, units, groups, and uncertainty.
Read guidemean median standard deviation study results
Mean, Median, and Standard Deviation: Reading Study Results
Mean, median, and standard deviation preserve different information and hide different details. Their usefulness depends on the distribution behind the summary.
Read guideconfidence intervals and effect sizes explained
How to Read Confidence Intervals and Effect Sizes
Start with the size of the observed effect, then read how much uncertainty surrounds it. A confidence interval helps with both questions but does not prove the result is true or clinically important.
Read guidehow to read research vial labels
Reading Research Vial Labels: Identity, Strength, and Units
A container label states certain facts and leaves others unknown. Read what is actually printed without inferring quality, suitability, identity, or use that the label does not establish.
Read guideclinical trial endpoints explained
Clinical trial endpoints: what a study measures and why it matters
An endpoint is a precisely defined measurement used to answer a trial question. Reading its variable, timing, analysis rule, and clinical meaning prevents a vague outcome label from becoming a broader claim than the study tested.
Read guideprimary vs secondary endpoints
Primary, secondary, and exploratory endpoints: why hierarchy matters
Endpoint hierarchy states which outcomes carry the trial's main confirmatory burden and which provide supporting or hypothesis-generating information. The label matters only when it was prespecified and analyzed with the planned error-control strategy.
Read guiderandomization in clinical trials
Randomization in clinical trials: sequence, balance, and valid comparison
Randomization uses chance to assign participants, protecting the comparison from systematic treatment selection and supporting valid uncertainty estimates. It works as a process, not as a guarantee that every measured baseline feature will match exactly.
Read guideblinding and masking in research
Blinding and masking in research: who knows what, and when
Blinding, also called masking, limits knowledge of assigned groups after allocation. Its value depends on exactly which people were unaware, whether the intervention could reveal itself, and how outcomes were measured.
Read guideallocation concealment vs blinding
Allocation concealment vs blinding: two protections at different times
Allocation concealment prevents upcoming assignments from influencing enrollment; blinding limits knowledge after assignment. Confusing the two can make a trial appear better protected than its actual process supports.
Read guideintention to treat vs per protocol
Intention-to-treat vs per-protocol: two different trial questions
Intention-to-treat preserves randomized groups, while per-protocol focuses on participants meeting defined adherence criteria. Neither label is complete without the estimand, exclusions, missing-data assumptions, and timing of the analysis rules.
Read guidestatistical power and sample size
Statistical power and sample size: what a study was designed to detect
Power is the probability that a planned analysis will detect a specified effect when that effect and the design assumptions are true. A sample-size calculation is therefore a transparent model of expectations, not a universal minimum or guarantee of a meaningful result.
Read guidemultiple comparisons false positives
Multiple comparisons: why more tests create more chances for false positives
Every hypothesis test has a chance of a false-positive conclusion. When many related tests are searched without a prespecified strategy, the probability that at least one looks positive by chance can increase substantially.
Read guidepreregistration protocols analysis plans
Preregistration, protocols, and analysis plans: separating prediction from discovery
Preregistration timestamps intended questions and methods before results can influence them. Protocols and statistical analysis plans add operational and analytic detail, while dated amendments show how a study evolved.
Read guideeligibility criteria external validity
Eligibility criteria and external validity: who a trial can inform
Eligibility criteria translate a research question into a study population. They can protect participants and reduce unwanted variation, but restrictive criteria may leave important uncertainty about people unlike those enrolled.
Read guideadverse events serious adverse events safety signals
Adverse events, serious adverse events, and safety signals: terms that are not interchangeable
An adverse event is an unfavorable occurrence after participation and does not by itself establish causality. Seriousness is defined by outcomes such as hospitalization or threat to life, while severity describes intensity and a safety signal is a pattern requiring evaluation.
Read guidetranslational research human evidence limits
Translational research: how findings move between models and human questions
Translational research connects basic mechanisms, preclinical models, human studies, implementation, and population outcomes. The process is iterative and can fail at multiple points, so a promising early result should retain its evidence stage.
Read guideassay validation sensitivity specificity range
Assay validation: proving a method is fit for its intended purpose
Assay validation is an intended-use argument supported by experiments. The required characteristics depend on whether the method identifies, quantifies, compares, or monitors a measurand and on the matrix and decision it supports.
Read guidebatch to batch variability research materials
Batch-to-batch variability: when the named material is not the same experiment
A shared material name does not guarantee identical identity, purity, composition, stability, or biological activity across batches. Lot-level documentation and bridging measurements help distinguish biological variability from material variability.
Read guidepurity identity contamination research materials
Purity, identity, and contamination: three separate analytical questions
Identity asks whether the intended molecule is present; purity asks what fraction of a defined measurement is assigned to it; contamination asks what unintended material entered the sample. One analytical number rarely resolves all three.
Read guidereplication vs reproducibility
Replication vs reproducibility: new evidence and repeatable analysis
Following the National Academies convention, reproducibility means obtaining consistent computational results from the same data, code, and methods; replicability means obtaining consistent findings with new data addressing the same question.
Read guidebias confounding effect modification
Bias, confounding, and effect modification: three different explanations for a result
Bias is systematic error, confounding distorts an association through another factor, and effect modification describes genuinely different effects across groups or contexts. They require different design, analysis, and reporting responses.
Read guidemissing data attrition censoring
Missing data, attrition, and censoring: assumptions behind incomplete outcomes
Missing data are not repaired by choosing a convenient imputation rule. Prevention, continued outcome collection, documented reasons, estimand alignment, and sensitivity analyses determine how much confidence an incomplete dataset can support.
Read guidepeptide stability and degradation
How Peptides Degrade and How Stability Is Studied
Peptide stability depends on identifiable degradation pathways and analytical methods capable of detecting meaningful change over time.
Read guidesolid phase peptide synthesis explained
How Solid-Phase Peptide Synthesis Builds a Sequence
Solid-phase peptide synthesis builds a chain step by step on a support. Its process logic explains why identity, impurities, yield, and purification require careful control, without serving as a laboratory recipe.
Read guiderecombinant peptide production
How Recombinant Systems Produce Peptides and Precursors
Recombinant production begins with an encoded construct, but the final product is the purified, processed, and characterized mature peptide. Those identities should not be conflated.
Read guidepeptide purification chromatography
How Chromatography Separates Peptides and Related Impurities
Peptide purification often requires more than one separation principle. A clean-looking chromatogram can support a purity question, but it does not establish molecular identity by itself.
Read guideanalytical characterization of peptides
No Single Test Fully Characterizes a Peptide
No single assay establishes every important peptide attribute. Identity, purity, quantity, structure, physical state, and biological activity usually require complementary methods.
Read guidepeptide mass spectrometry identity
What Mass Spectrometry Can and Cannot Prove About a Peptide
Mass agreement, fragment evidence, modification localization, and full molecular identity are different levels of support in peptide mass spectrometry.
Read guidepeptide sequence databases
How to Use Peptide Sequence Databases Without Losing Context
A peptide sequence database can connect a string to an organism, precursor, processing annotation, stable identifier, and supporting evidence. The strength of that connection depends on the underlying record.
Read guide6 guides
Math and units
SI units in peptide research
How SI Units and Metric Prefixes Work in Research
Learn to read small research quantities by identifying the unit before interpreting the number. That habit separates the measured quantity from its notation and helps prevent thousand-fold prefix errors.
Read guidedilution factor explained
Dilution Factors and Serial Dilutions: The Underlying Math
See how dilution changes concentration, how stepwise dilution factors combine, and why a correct equation cannot account for every preparation detail.
Read guidefinal concentration after solvent addition
How Solvent Addition Changes Final Concentration
When a record gives a total mass and a final volume, their mathematical relationship can be read without turning the result into a practical procedure.
Read guidedimensional analysis research calculations
Dimensional Analysis: A Safer Way to Check Research Math
Treating units as algebra makes conversion chains easier to audit. It also reveals when a calculation is dimensionally valid but still fails to answer the intended research question.
Read guidescientific notation in research
Scientific Notation for Reading Small Research Quantities
Translate among decimal notation, scientific notation, and metric prefixes without losing track of scale or units.
Read guidemass concentration volume explained
Mass, Concentration, and Volume Are Different Quantities
Mass, concentration, and volume are distinct quantities connected by a simple equation. Understanding that relationship does not turn it into individualized guidance.
Read guide16 guides
Glossary
peptide vs protein
Peptide vs protein: what the terms mean and where the boundary blurs
Peptides and proteins are built from amino acids joined by peptide bonds, but scientific naming depends on more than a universal length cutoff. Structure, folding, function, biosynthesis, and field-specific convention all contribute.
Read guidepeptide aliases and nomenclature
Peptide aliases and nomenclature: how to verify that two names mean the same molecule
A peptide name may refer to a sequence, development program, drug ingredient, modification, fragment, or informal vendor label. Resolve the molecular identity before attaching a paper to it or comparing it with another compound.
Read guideconcentration dose volume glossary
Concentration, Dose, Amount, and Volume: A Research Glossary
Concentration, mass, volume, and dose are often used as though they mean the same thing. This glossary keeps the quantities distinct when reading studies, labels, and experimental records.
Read guideclinical trial phases explained
Clinical trial phases explained: development questions, not quality grades
Clinical trial phases describe the development questions a study is designed to address. They are not rankings of evidence quality, and phase labels do not replace inspection of design, population, endpoints, results, and current regulatory status.
Read guidepharmacokinetics basics ADME
Pharmacokinetics basics: absorption, distribution, metabolism, and elimination
Pharmacokinetics describes how a studied compound moves through a biological system over time. ADME is a useful map, while measured concentration-time data and model assumptions determine the actual parameters reported.
Read guidebiological half life steady state
Biological half-life and steady state: what concentration-time summaries assume
Elimination half-life describes how long a modeled concentration takes to fall by half under stated conditions. Steady state describes a dynamic balance between input and elimination, not the moment a compound becomes effective or safe.
Read guidebioavailability route comparison
Bioavailability and route comparisons: rate, extent, and formulation context
Bioavailability describes the rate and extent to which a measured active moiety becomes available in systemic circulation or another defined domain. Route and formulation comparisons require matched products, validated assays, and prespecified exposure measures.
Read guideagonist antagonist partial agonist
Receptor agonists, antagonists, and partial agonists: a functional glossary
Agonist and antagonist labels describe functional behavior in a defined receptor system. The observed response depends on receptor expression, signaling pathway, assay timing, and comparator, so the same ligand can appear different across experimental contexts.
Read guideselectivity vs specificity pharmacology
Selectivity vs specificity: relative preference, assay discrimination, and context
Selectivity usually describes relative preference among targets or signals, while analytical specificity concerns distinguishing the intended analyte or response from interference. Neither should be presented as an absolute property without conditions.
Read guidepotency vs efficacy
Potency vs efficacy: position and maximum on a concentration-response curve
Potency describes how much concentration is associated with a defined response in an assay; efficacy describes the maximal response a ligand can produce in that system. They are different properties and neither alone establishes clinical value.
Read guideKd IC50 EC50 affinity explained
Affinity, Kd, IC50, and EC50: binding constants and operational assay values
Kd is an equilibrium binding quantity, whereas IC50 and EC50 are operational values derived from inhibition or activation curves. Assay format, ligand concentration, receptor system, controls, and curve fitting determine what each value can support.
Read guidein vitro in vivo ex vivo explained
In vitro, in vivo, and ex vivo: three model contexts with different limits
In vitro research studies components outside an intact organism, in vivo research studies processes within a living organism, and ex vivo research studies removed cells, tissues, or organs. Each trades experimental control against biological context.
Read guidereference standards and calibration
Reference standards and calibration: connecting an instrument response to a known value
Reference materials provide characterized values or properties that anchor measurement. Calibration relates instrument response to those values, while traceability and uncertainty document how confidently the result connects to a higher-order reference.
Read guideHPLC chromatography basics
Chromatography and HPLC basics: separation, retention, detection, and limits
Chromatography separates sample components through different interactions with stationary and mobile phases. HPLC data can support identity, assay, and impurity questions, but only within a validated method and with a detector suited to the measurands.
Read guidemass spectrometry basics
Mass spectrometry basics: ions, mass-to-charge, fragmentation, and identification
Mass spectrometry measures ions according to mass-to-charge behavior and can add molecular-mass and fragmentation evidence. Confidence depends on calibration, ionization, resolution, sample preparation, database quality, and orthogonal context.
Read guidepeptide naming and sequence identity
A Peptide Name Is Not a Complete Molecular Identity
An ambiguous peptide label becomes useful only when it can be tied to a traceable molecular record. Similar or synonymous names do not guarantee identical products.
Read guide